This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting. GS-US-595-6184

Location: REDI (East Bay) - Contact: Nhu Tran, CRC

Location: SIMR (Sacramento/Valley Area) - Contact: SIMR@sutterhealth.org

Principal Investigator

Nitin Rohatgi, MD, Uma Suryadevara, MD